AstraZeneca (AZN) Projected to Announce Earnings on Friday

AstraZeneca (NYSE:AZN) is anticipated to release its Q3 2026 results before the market opens on Friday, October 30th. Analysts expect the company to announce earnings of $2.60 per share and revenue of $16.01 billion for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, October 30, 2026 at 10:30 AM ET.

AstraZeneca (NYSE:AZN) last announced its quarterly earnings data on Monday, July 27th. The company reported $2.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.13. The firm had revenue of $15.38 billion during the quarter, compared to analysts’ expectations of $15.44 billion. During the same period last year, the company earned $2.17 earnings per share. The business’s revenue for the quarter was up 6.4% on a year-over-year basis. On average, analysts expect AstraZeneca to post $10.23 EPS for the current fiscal year and $11.37 EPS for the next fiscal year.

AstraZeneca Stock Performance

AZN opened at $170.04 on Wednesday. AstraZeneca has a fifty-two week low of $153.41 and a fifty-two week high of $212.71. The firm’s fifty day moving average is $163.68 and its 200 day moving average is $180.39. The stock has a market cap of $263.71 billion, a price-to-earnings ratio of 25.42 and a beta of 0.27.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. JPMorgan Chase & Co. reissued a “buy” rating on shares of AstraZeneca in a report on Tuesday, June 30th. Bank of America restated a “buy” rating on shares of AstraZeneca in a research report on Wednesday, July 1st. Nordea Equity Research raised AstraZeneca from a “sell” rating to a “buy” rating in a research note on Tuesday, October 13th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, September 15th. Finally, Weiss Ratings raised AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday. Sixteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $206.67.

About AstraZeneca

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.